AR079429A1 - Capsulas de principios activos farmaceuticos y esteres de acidos grasos poliinsaturados - Google Patents

Capsulas de principios activos farmaceuticos y esteres de acidos grasos poliinsaturados

Info

Publication number
AR079429A1
AR079429A1 ARP100104271A ARP100104271A AR079429A1 AR 079429 A1 AR079429 A1 AR 079429A1 AR P100104271 A ARP100104271 A AR P100104271A AR P100104271 A ARP100104271 A AR P100104271A AR 079429 A1 AR079429 A1 AR 079429A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical
capsule according
pharmaceutical capsule
fatty acids
microcapsules
Prior art date
Application number
ARP100104271A
Other languages
English (en)
Inventor
Duena Antonio Parente
Paolo Carminati
Original Assignee
Defiante Farmaceutica Sa
Gp Pharm Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Defiante Farmaceutica Sa, Gp Pharm Sa filed Critical Defiante Farmaceutica Sa
Publication of AR079429A1 publication Critical patent/AR079429A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A61K9/5057—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composicion farmacéutica en forma de cápsula que contiene ésteres alquílicos de ácidos grasos poliinsaturados (PUFA) y principios activos farmacéuticos para el tratamiento y/o prevencion de enfermedades cardiovasculares y/o procesos inflamatorios. Reivindicacion 1: Cápsula farmacéutica que comprende una suspension de microcápsulas poliméricas que comprenden al menos un polímero y al menos un principio activo farmacéutico seleccionado del grupo formado por antagonistas de los canales de calcio, betabloqueantes, antiagregantes plaquetarios, anticoagulantes y antiinflamatorios no esteroideos, estando dichas microcápsulas suspendidas en un aceite que contiene ésteres alquílicos de ácidos grasos poliinsaturados. Reivindicacion 2: Cápsula farmacéutica segun la reivindicacion 1, donde los ácidos grasos poliinsaturados de dichos ésteres alquílicos pertenecen a la serie omega-3. Reivindicacion 3: Cápsula farmacéutica segun la reivindicacion 2, donde los ácidos grasos poliinsaturados de dichos ésteres alquílicos se seleccionan del grupo formado por ácido eicosapentaenoico, ácido docosahexaenoico, y/o sus mezclas. Reivindicacion 12: Cápsula farmacéutica segun la reivindicacion 1, donde el polímero de dichas microcápsulas se selecciona del grupo formado por proteínas, poliésteres, poliacrilatos, policianoacrilatos, polisacáridos, polietilenglicol y/o sus mezclas. Reivindicacion 14: Cápsula farmacéutica segun la reivindicacion 1, donde dichas microcápsulas representan entre el 0,001% y el 80% del peso total de la cápsula. Reivindicacion 17: Cápsula farmacéutica segun la reivindicacion 1, donde la composicion de la cubierta de dicha cápsula se selecciona del grupo formado por gelatina, hidroxipropilmetilcelulosa, pululano, almidones modificados, carragenanos y/o sus mezclas. Reivindicacion 19: Cápsula farmacéutica segun la reivindicacion 1, donde dicha cápsula tiene un recubrimiento entérico. Reivindicacion 20: Cápsula farmacéutica segun la reivindicacion 1, para el tratamiento y/o prevencion de enfermedades cardiovasculares. Reivindicacion 21: Cápsula farmacéutica segun la reivindicacion 1, para el tratamiento de enfermedades y/o procesos que cursan con inflamacion y/o dolor.
ARP100104271A 2009-11-20 2010-11-18 Capsulas de principios activos farmaceuticos y esteres de acidos grasos poliinsaturados AR079429A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200931026A ES2363964B1 (es) 2009-11-20 2009-11-20 Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados.

Publications (1)

Publication Number Publication Date
AR079429A1 true AR079429A1 (es) 2012-01-25

Family

ID=43498493

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100104271A AR079429A1 (es) 2009-11-20 2010-11-18 Capsulas de principios activos farmaceuticos y esteres de acidos grasos poliinsaturados

Country Status (4)

Country Link
AR (1) AR079429A1 (es)
ES (1) ES2363964B1 (es)
TW (1) TW201141470A (es)
WO (1) WO2011060944A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2385240B1 (es) * 2010-07-26 2013-09-23 Gp-Pharm, S.A. Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata.
ITMI20112221A1 (it) 2011-12-05 2013-06-06 Altergon Sa Formulazioni stabili in capsule di gelatina molle di antiaggreganti piastrinici, acidi grassi omega-3 e amilosio
EP2836206A4 (en) * 2012-04-10 2015-11-04 Rubicon Res Private Ltd PHARMACEUTICAL FORMULATIONS WITH CONTROLLED RELEASE OF DIRECT THROMBINS
WO2014007779A1 (en) * 2012-07-06 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Orally-disintegrating formulations of dexketoprofen
WO2014007780A1 (en) * 2012-07-06 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Orally-disintegrating formulations of dexketoprofen
CN103626689B (zh) * 2012-08-24 2016-03-09 上海医药工业研究院 一种阿哌沙班的中间体的制备方法
WO2015195990A1 (en) * 2014-06-20 2015-12-23 Banner Life Sciences Llc Liquid-filled immediate release soft gelatin capsules
CN106620707B (zh) * 2017-03-14 2019-06-07 牡丹江医学院 一种预防和治疗心肌缺血的药物组合物及其制备方法和用途
WO2019178444A1 (en) 2018-03-15 2019-09-19 R.P. Scherer Technologies, Llc Enteric softgel capsules
CN114869857B (zh) * 2022-05-12 2023-04-04 郑州大学第一附属医院 一种阿加曲班微粒、制剂及其制备方法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5312473B1 (es) 1971-05-24 1978-05-01
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
JPS5920230A (ja) 1982-07-19 1984-02-01 チバ−ガイギ−・アクチエンゲゼルシヤフト ピルプロフエン含有薬剤
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4609675A (en) 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US4857552A (en) 1988-06-08 1989-08-15 E. I. Du Pont De Nemours And Co. Stable pharmaceutical composition
US4954346A (en) 1988-06-08 1990-09-04 Ciba-Geigy Corporation Orally administrable nifedipine solution in a solid light resistant dosage form
US5035896A (en) 1988-06-15 1991-07-30 Warner-Lambert Company Water insoluble drugs coated by coacervated fish gelatin
FR2660555B1 (fr) 1990-04-06 1994-09-16 Rhone Poulenc Sante Gelule huileuse de ketoprofene.
EP0524180B1 (en) 1990-04-11 1995-04-26 The Upjohn Company Taste masking of ibuprofen by fluid bed coating
CA2039742A1 (en) 1990-04-23 1991-10-24 Andrew B. Dennis Tablet composition and method for problem pharmaceutical materials
CH683149A5 (fr) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
ZA945944B (en) 1993-08-13 1996-02-08 Eurand America Inc Procedure for encapsulating nsaids
DE69534258T2 (de) 1994-03-15 2006-05-04 Mitsubishi Pharma Corp. Verfahren zur Stabilisierung von Pranoprofen und stabile flüssige Zubereitung von Pranoprofen
US5447729A (en) 1994-04-07 1995-09-05 Pharmavene, Inc. Multilamellar drug delivery systems
GB2290965A (en) 1994-07-11 1996-01-17 Therapicon Srl Multiple layer capsules for drugs
EP0839029A1 (en) 1995-07-20 1998-05-06 PHARMACIA & UPJOHN COMPANY Stable clear solutions of non-steroidal anti-inflammatory drugs for incorporation into gelatin capsules
WO1997033568A1 (en) 1996-03-12 1997-09-18 Novartis Ag Filled gelatin capsules having a reduced degree of cross-linking
US6251426B1 (en) 1999-09-02 2001-06-26 Banner Pharmacaps, Inc. Ibuprofen-containing softgels
EP1214059B1 (en) 1999-09-21 2005-05-25 Skyepharma Canada Inc. Surface modified particulate compositions of biologically active substances
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE10026699A1 (de) 2000-05-30 2001-12-06 Basf Ag Formulierung auf Heparin-, Glycosaminoglycan- oder Heparinoidbasis und Verwendung der Formulierung sowie der Formulierungsgrundlage
JP3553562B2 (ja) 2000-08-25 2004-08-11 興和株式会社 イブプロフェンカプセル充填液及びカプセル製剤
US6387400B1 (en) 2000-08-29 2002-05-14 R.P. Scherer Technologies, Inc. Process for preparing pharmaceutical compositions for use with soft gelatin formulations
TWI277414B (en) 2001-01-12 2007-04-01 Baxter Int Esmolol formulation
US6673944B2 (en) 2001-02-28 2004-01-06 Taro Pharmaceutical Industries, Ltd. Preparation of warfarin sodium from warfarin acid
ITMI20020731A1 (it) * 2002-04-08 2003-10-08 Ibsa Inst Biochimique Sa Composizioni farmaceutiche per acido acetilsalicilico e oli omega-3
ITFI20020144A1 (it) 2002-08-01 2004-02-02 Menarini Farma Ind Formulazioni topiche stabilizzate contenenti ketoprofene.
US20040115226A1 (en) 2002-12-12 2004-06-17 Wenji Li Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same
GB0325603D0 (en) 2003-11-03 2003-12-10 Sandoz Ag Organic compounds
EP1686986A4 (en) 2003-11-25 2009-05-27 Sb Pharmco Inc CARVEDILOL SALTS, CORRESPONDING COMPOSITIONS, METHODS OF ADMINISTRATION AND / OR TREATMENT
US20080311207A1 (en) 2004-09-08 2008-12-18 Manoj Varshney Micelles and Nanoemulsions for Preventive and Reactive Treatment of Atherosclerosis
JP4509118B2 (ja) 2004-10-06 2010-07-21 エルメッド エーザイ株式会社 医薬組成物及びその製造方法、並びに医薬組成物におけるジヒドロピリジン系化合物の安定化方法
ES2255426B1 (es) * 2004-10-19 2007-08-16 Gp Pharm, S.A. Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
WO2006081518A2 (en) 2005-01-28 2006-08-03 Collegium Pharmaceutical, Inc. Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents
DK1688129T3 (en) 2005-02-02 2015-10-05 Omega Pharma Innovation & Developement N V New therapeutic formulation
EP1990049A3 (en) * 2005-03-21 2008-11-26 Vicus Therapeutics SPE 1, LLC Combination therapy of beta-blockers and non-steroidal anti-inflammatory drugs (NSAID)
BRPI0614417A2 (pt) * 2005-07-28 2011-03-29 Reliant Pharmaceuticals Inc composições farmacêuticas compreendendo bloqueadores de canais de cálcio de dihidropiridina e ácidos graxos de Èmega-3 e métodos de tratamento utilizando as mesmas
WO2007103557A2 (en) * 2006-03-09 2007-09-13 Reliant Pharmaceuticals, Inc. Coating capsules with active pharmaceutical ingredients
KR100913791B1 (ko) 2006-07-21 2009-08-26 한미약품 주식회사 (ｓ)-(-)-암로디핀 캠실레이트 또는 이의 수화물 및 이를함유하는 약학적 조성물
WO2008062435A2 (en) 2006-08-15 2008-05-29 Alkem Laboratories Ltd. Stabilised dosage forms of amlodipine besylate
EP1894561A1 (en) 2006-08-30 2008-03-05 Dr. Reddy's Laboratories Ltd. Dipyridamole pharmaceutical compositions
ATE498626T1 (de) 2006-09-25 2011-03-15 Adamed Sp Zoo Neues clopidogrel-salz und seine kristallinen formen
CN101557805A (zh) 2006-10-13 2009-10-14 瑞莱恩特医药品有限公司 使用抗心律不齐药和ω-3脂肪酸的治疗及其组合产品
US7749537B2 (en) 2006-12-04 2010-07-06 Scolr Pharma, Inc. Method of forming a tablet
WO2008070950A1 (en) 2006-12-13 2008-06-19 Laboratoires Mauves Inc. Pharmaceutical solution formulations for encapsulation into gelatin capsules or other dosage forms
KR20080055356A (ko) 2006-12-15 2008-06-19 에스케이케미칼주식회사 보관안정성이 우수한 클로피도그렐 함유 포접 복합체
WO2008088808A1 (en) 2007-01-16 2008-07-24 Reliant Pharmaceuticals, Inc. Treatment with non-steroidal anti-inflammatory drugs and omega-3 fatty acids, and a combination product thereof
BRPI0810168A2 (pt) 2007-04-09 2014-12-30 Usv Ltd Composições farmacêuticas de bissulfato de clopidogrel e processos de preparação das mesmas
WO2008132710A2 (en) * 2007-05-01 2008-11-06 Sigmoid Pharma Limited Pharmaceutical nimodipine compositions

Also Published As

Publication number Publication date
ES2363964A1 (es) 2011-08-22
TW201141470A (en) 2011-12-01
WO2011060944A3 (en) 2012-05-03
WO2011060944A2 (en) 2011-05-26
ES2363964B1 (es) 2012-08-22
WO2011060944A8 (en) 2011-10-27

Similar Documents

Publication Publication Date Title
AR079429A1 (es) Capsulas de principios activos farmaceuticos y esteres de acidos grasos poliinsaturados
HRP20200065T1 (hr) Upotreba etilnog estera ikozapentaenske kiseline u liječenju hipertrigliceridemije
PE20142459A1 (es) Composiciones enriquecidas con dpa de acidos grasos omega 3 poliinsaturados en forma de acido libre
ES2279864T3 (es) Potenciacion de los efectos terapeuticos de los acidos grasos poliinsaturados.
MX2012005744A (es) Capsulas de principios activos farmaceuticos y esteres de acidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
PE20170253A1 (es) Lipido que comprende acidos grasos poliinsaturados de cadena larga
JP2015143248A5 (es)
AR122580A2 (es) Forma de dosificación de doxilamina y piridoxina y/o sus metabolitos o sales
JP2015527386A5 (es)
MX356427B (es) Emulsion que contiene hormona.
JP2014512351A5 (es)
MX2014000770A (es) Composiciones de acidos grasos.
WO2006078457A3 (en) Use of resolvins to treat gastrointestinal diseases
JP2014231513A5 (es)
PE20091076A1 (es) Composicion que comprende acidos grasos poliinsaturados y carbon vegetal activado
BR112021010335A2 (pt) Preparação que compreende uma cepa probiótica e um componente de ácido graxo poli-insaturado
AR110343A1 (es) Composiciones nutricionales que contienen butirato y usos de las mismas
BR112015013988A2 (pt) revestimentos abrasivos para composições contendo peróxido
EA201591680A1 (ru) Смесь жирных кислот (гжк, группа жирных кислот) и её применение для лечения воспалительных патологий
BR112018001164A2 (pt) composto de fórmula geral, composição farmacêutica e método para o tratamento de uma doença cardiovascular
JP2017514874A5 (es)
EA201200935A1 (ru) Комбинированная композиция, подходящая для лечения сердечно-сосудистых заболеваний
FI3177281T3 (fi) Rasvahappojen ja palmitoyylietanoliamidin seos käytettäväksi tulehduksellisten ja allergisten patologioiden hoitoon
AR101724A1 (es) COMPOSICIÓN FARMACÉUTICA Y COMBINACIÓN TERAPÉUTICA QUE COMPRENDE UN INHIBIDOR DE LA PROTEÍNA DE TRANSFERENCIA DEL ÉSTER COLESTERILO E INHIBIDORES DE LA HMG CoA REDUCTASA
EP2853263A4 (en) MULTILAYER COATING OF ORAL-ADMINISTRATIVE, PHARMACEUTICAL COMPOSITION WITH OMEGA-3-FATTY ACID OR ALKYLESTER THEREOF AND STATINE-BASED ACTIVE SUBSTANCE

Legal Events

Date Code Title Description
FB Suspension of granting procedure